Results 71 to 80 of about 5,892 (166)

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

Hepatology Research, Volume 56, Issue 6, Page 925-932, June 2026.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano, Taeang Arai, Hidenori Toyoda, Keizo Kato, Joji Tani, Suguru Ogura, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Toshifumi Tada, Akito Nozaki, Atsushi Hiraoka, Kentaro Matsuura, Toru Ishikawa, Naoto Kawabe, Tsunamasa Watanabe, Koichi Takaguchi, Asahiro Morishita, Hironao Okubo, Motoh Iwasa, Hiroki Nishikawa, Yasuhito Tanaka, Masanori Atsukawa   +22 more
wiley   +1 more source

Potential amelioration of liver function by low-dose tolvaptan in heart failure patients

Toxicology Reports
Aim: This study aimed to evaluate the relationships between the pharmacokinetics of tolvaptan and its metabolites (DM-4103 and DM-4107) and liver injury in heart failure patients, using relevant laboratory test values and markers of hepatocyte injury and
Yasuaki Mino, Kohei Hoshikawa, Takafumi Naito, Shunta Akutsu, Yumi Imoto, Emi Nakatsugawa, Masao Saotome, Yuichiro Maekawa, Junichi Kawakami   +8 more
doaj   +1 more source

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report

BMC Nephrology, 2019
Background Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by the presence of renal cysts. Over time the expanding cysts lead to progressive renal failure.
Angela Maria Pellegrino, Luigi Annicchiarico Petruzzelli, Eleonora Riccio, Antonio Pisani   +3 more
doaj   +1 more source

Tolvaptan and its potential in the treatment of hyponatremia

, 2008
Megan B Dixon, Y Howard LienDepartment of Medicine, University of Arizona, Arizona Kidney Disease and Hypertension Center, Tucson, Arizona, USAAbstract: Tolvaptan is a selective arginine vasopressin (AVP) V2 receptor blocker used to induce free water ...
Y Howard Lien, Megan B Dixon
core  

V2 Receptor Antagonist: Tolvaptan

, 2011
Hyponatremia is the most common electrolyte disorder in hospitalized patients. Many studies documented that it was related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases.
���������
core   +1 more source

Pituitary Neurolobectomy induces sustained hypotension in male Wistar rats and normalizes blood pressure in male spontaneously hypertensive rats

Physiological Reports, Volume 14, Issue 11, June 2026.
Abstract Arginine vasopressin is primarily recognized as an osmoregulatory hormone; however, its contribution to vascular tone and blood pressure regulation under basal and hypertensive conditions remains debated. This study examined the effects of vasopressin deficiency induced by neurointermediate pituitary lobectomy in Wistar and spontaneously ...
Gloria Marcela Villanueva‐Rodríguez, Norma A. Bobadilla, J. Luis Quintanar, Claudia Verónica Rivera‐Cerecedo, David Roberto Chavira‐Ramírez, Kalman Kovacs, Andrés Quintanar‐Stephano   +6 more
wiley   +1 more source

Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients

, 2010
Savina Nodari1, Geoffrey T Jao2, Jun R Chiong31Division of Cardiology, University of Brescia, Brescia, Italy; 2Section of General Internal Medicine, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA; 3Division of Cardiology, Loma ...
Savina Nodari, Geoffrey T Jao, Jun R Chiong   +2 more
core  

Best Evidence Summary for Volume Management of Patients With Heart and Kidney Comorbidity

Nursing Open, Volume 13, Issue 5, May 2026.
ABSTRACT Objective To summarise the best evidence of volume management of patients with coexisting cardiac and renal disorders. Design An evidence summary, a form of rapid review. Methods A systematic search was conducted in guideline websites, professional association websites and six databases included Web of Science, Embase, CIHAHL, PubMed, CNKI ...
Huang Aoli, Chen Xia, Zhu Xujing, Yang Qiaozhen, Yang Yeyao, Feng Jiehui   +5 more
wiley   +1 more source

Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload

, 2018
Shunji Suzuki,1,2 Norio Hanafusa,3 Kenji Kubota,1 Ken Tsuchiya,3 Kosaku Nitta2 1Department of Nephrology, Kawaguchi Saiseikai Hospital, Kawaguchi, Japan; 2Department of Medicine, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan ...
Tsuchiya K, Kubota K, Suzuki S, Nitta K, Hanafusa N   +4 more
core  

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]

, 2018
Muto S, Okada T, Yasuda M, et al. Drug Healthc Patient Saf. 2017;9:93–104.On page 97, ‘Discussion’ section, lines 10–13, left column, the sentence: ‘Similarly, placebo patients who crossed over onto active treatment ...
Nakajima K, Yasuda M, Horie S, Muto S, Tsubouchi H, Okada T   +5 more
core